$0 to $10,275. $0 to $20,550. $0 to $10,275. $0 to $14,650. $10,276 to $41,775. $20,551 to $83,550. $10,276 to $41,775. $14,651 to $55,900. $41,776 to $89,075 ...

This is how I would re-draft the 2025 NFL Draft if I had a crystal ball for how last season would play out. Winning a Lombardi Trophy requires three key ingredients: a quality quarterback, an elite ...

In 2025, the initial public offering (IPO) market continued to rebound from the 2022 and 2023 slump. For the second year in a row, markets saw more IPOs, more special purpose acquisition companies ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. Project 2025, a conservative think tank’s blueprint to reshape the United States under a Republican president, recognized ...

Tax season is approaching, and millions of Americans will soon turn their attention to tax brackets. Every year, the Internal Revenue Service announces new tax brackets, tiers of income that are taxed ...

From battlefronts in Ukraine to the destruction in Gaza, 2025 was marked by conflict, political upheaval and extreme weather across the globe. The year saw Trump’s meetings on the world stage, the ...

Boy oh boy, have the 2025 NFL playoffs been interesting. Let's take a minute to reflect on the last month, shall we? The postseason began as follows: The Seahawks were in charge of the No. 1 seed in ...

Drug developers secured approvals for 46 new therapeutic agents from the FDA’s Center for Drug Evaluation and Research (CDER) in 2025. This cohort brings the 5-year average down a touch, to 48 new ...

Forbes contributors publish independent expert analyses and insights. I cover the intersection of people, risk, leadership and performance. This voice experience is generated by AI. Learn more. This ...

It's been a great year for movies. Revisit the best of the best, already on Netflix, HBO Max, and more. 2025 has come to an end, and with it comes a lot of reflection, both in terms of how the world ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series of political decisions ...